首页> 外文期刊>Pediatric Pulmonology >KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice.
【24h】

KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice.

机译:KL4表面活性剂可防止高氧和LPS诱导的小鼠肺损伤。

获取原文
获取原文并翻译 | 示例
       

摘要

KL(4)-surfactant contains the novel KL(4) peptide, sinapultide, which mimics properties of the hydrophobic pulmonary surfactant protein SP-B, in a phospholipid formulation and may be lung protective in experimental acute respiratory distress syndrome/acute lung injury. Our objective was to determine the protective role of airway delivery of KL(4)-surfactant in murine models of hyperoxic and lipopolysaccharide (LPS)-induced lung injury and further explore the mechanisms of protection. For the hyperoxic injury model, mice exposed to 80% O(2) for 6 days received an intranasal bolus of vehicle, beractant, or KL(4)-surfactant on days 3, 4, 5, and 6 of the exposure, and lungs were evaluated on day 7. Mice in the LPS-induced lung injury model received an intratracheal bolus of LPS followed by an intranasal bolus of KL(4)-surfactant or control at 1, 3, and 19 hr post-LPS challenge, and lungs were evaluated after 24 hr. To explore the mechanisms of protection, in vitro assays were performed with human and murine endothelial cell monolayers, and polymorphonuclear leukocyte (PMN) transmigration in the presence or absence of KL(4)-surfactant or lipid controls was evaluated. Based on morphology, histopathology, white blood cell count, percentage of PMNs, and protein concentration in bronchoalveolar lavage fluid, our data showed KL(4)-surfactant, unlike vehicle or beractant, blocked neutrophil influx into alveoli and suppressed lung injury. Furthermore, in vitro assays showed KL(4)-surfactant decreased neutrophil transmigration at the endothelial cell level. KL(4)-surfactant decreased inflammation and lung permeability compared with controls in both mouse models of lung injury. Evidence suggests the anti-inflammatory mechanism of the KL(4)-peptide is through inhibition of PMN transmigration through the endothelium.
机译:KL(4)-表面活性剂在磷脂制剂中包含新型KL(4)肽sinapultide,其模拟疏水性肺表面活性剂蛋白SP-B的特性,在实验性急性呼吸窘迫综合征/急性肺损伤中可能具有肺保护作用。我们的目标是确定在高氧和脂多糖(LPS)诱导的肺损伤小鼠模型中气道递送KL(4)-表面活性剂的保护作用,并进一步探讨保护机制。对于高氧损伤模型,暴露于80%O(2)达6天的小鼠在暴露的第3、4、5和6天和肺部接受鼻内溶媒,beractant或KL(4)-表面活性剂的推注在第7天进行了评估。LPS激发后,在LPS诱发的肺损伤模型中的小鼠在气管内推注LPS,然后在1、3、19 hr和KL(4)-表面活性剂或对照组的鼻内推注,并接受了肺24小时后评估。为了探索保护的机制,对人和鼠的内皮细胞单层进行了体外测定,并评估了在存在或不存在KL(4)-表面活性剂或脂质对照的情况下多形核白细胞(PMN)的迁移。基于形态学,组织病理学,白细胞计数,PMN百分数和支气管肺泡灌洗液中的蛋白质浓度,我们的数据显示,与媒介物或甜菜碱不同,KL(4)-表面活性剂可阻止中性粒细胞流入肺泡并抑制肺损伤。此外,体外测定显示KL(4)-表面活性剂在内皮细胞水平上减少了嗜中性粒细胞的迁移。在两个小鼠肺损伤模型中,与对照组相比,KL(4)-表面活性剂减少了炎症和肺通透性。有证据表明,KL(4)肽的抗炎机制是通过抑制PMN通过内皮的迁移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号